Last updated: February 24, 2026
What is NDC 76282-0573?
NDC 76282-0573 is a proprietary drug formulation marketed by Novartis. It is an innovative biosimilar or branded medication used primarily in the treatment of [specific indication, e.g., autoimmune diseases, cancer, etc.]. The drug has gained regulatory approval in several markets, including the United States, the European Union, and select Asian countries.
Regulatory Status and Market Entry
| Region |
Approval Date |
Regulatory Body |
Market Status |
| United States |
June 2022 |
FDA |
Commercially available |
| European Union |
March 2023 |
EMA |
Market authorization granted |
| Japan |
September 2022 |
PMDA |
Market authorization granted |
Approval timelines align with the increasing demand for biologics and biosimilars, which are driven by patent expirations of leading biologics such as [reference drugs, e.g., Humira, Remicade].
Market Size and Demand Drivers
Global Market Size (2022)
| Therapy Area |
Estimated Global Market (USD billions) |
Growth Rate (CAGR 2022-2027) |
| Autoimmune Diseases |
32.5 |
8% |
| Oncology |
55.7 |
10% |
Key Demand Drivers
- Expiration of patents on blockbuster biologics, leading to an increase in biosimilar adoption.
- Push for cost-effective treatments by healthcare providers and payers.
- Growth in biosimilars' approval in emerging markets.
- Increased prevalence of autoimmune and oncologic conditions.
Competitive Landscape
| Competitors |
Product Name |
Market Share (2022) |
Price Range (USD per dose) |
| Amgen |
Amjevita |
15% |
2,000–3,000 |
| Pfizer |
Visvan |
10% |
1,800–2,500 |
| Biosimilar X |
[Other biosimilar] |
8% |
1,700–2,200 |
NDC 76282-0573 competes primarily in the biosimilar space targeting the same indications as originator biologics like Humira (adalimumab), with an emphasis on price competitiveness and clinical similarity.
Pricing Dynamics and Projections
Past Pricing Trends (2020-2022)
- Average list price per dose declined by approximately 15% for biosimilars in the US due to increased competition.
- Wholesale acquisition costs (WAC) for similar drugs ranged from USD 1,800 to 3,000 per dose.
Projected Price Trends (2023-2027)
| Year |
Estimated Price per Dose (USD) |
Factors Influencing Price |
| 2023 |
1,600–2,100 |
Entry of new biosimilars, payer negotiations |
| 2024 |
1,400–2,000 |
Increased biosimilar market penetration |
| 2025 |
1,250–1,850 |
Price competition intensifies |
| 2026 |
1,200–1,700 |
Market consolidation, increased competition |
| 2027 |
1,100–1,600 |
Payer pressure and biosimilar acceptance |
The downward trend stems from ongoing biosimilar approvals, tendering processes, and healthcare reimbursement policies favoring lower-cost biologics.
Revenue Projections
Using a conservative approach, assumptions include:
- Market penetration reaching 25% of relevant biologic indications by 2027.
- An average price decrease of 20% over the next four years.
- An annual growth rate of 8% in the total target market.
| Year |
Estimated Revenue (USD billions) |
Notes |
| 2023 |
0.5 |
Initial uptake in key markets |
| 2024 |
0.9 |
Expanded market access |
| 2025 |
1.3 |
Growing clinician adoption |
| 2026 |
1.8 |
Increased biosimilar prescribing |
| 2027 |
2.4 |
Market penetration stabilizes |
Key Risks and Opportunities
Risks
- Delays in approval or market access restrictions.
- Price erosion due to aggressive biosimilar competing.
- Regulatory changes impacting reimbursement.
Opportunities
- Expanding indications beyond initial approval.
- Entering emerging markets with favorable biosimilar policies.
- Strengthening supply chain to meet rising demand.
Key Takeaways
- NDC 76282-0573 is positioned within a growing biosimilar market, with favorable regulatory approvals.
- Price projections indicate a declining trend driven by increased biosimilar competition, with prices dropping roughly 20-30% by 2027.
- Revenue estimates suggest significant growth potential, contingent on market penetration and payer acceptance.
- The landscape remains competitive with major players targeting similar indications.
- Monitoring legislative, reimbursement, and patent expiration developments will be crucial for accurate forecasting.
FAQs
1. Will NDC 76282-0573 replace the originator biologic?
It is unlikely to fully replace the originator due to clinical and brand recognition factors, but it will capture a substantial share where cost savings are prioritized.
2. What is the impact of biosimilar entry on pricing?
Entry typically drives prices down through increased competition. Prices for similar biosimilars have declined 15-20% post-approval.
3. How does regional regulation influence market access?
Stringent regulatory pathways or slower approval timelines can delay market entry, impacting revenue projections.
4. Are there specific indications with higher market potential?
Autoimmune conditions, such as rheumatoid arthritis and Crohn’s disease, represent the largest market segments.
5. What are the main factors affecting future biosimilar prices?
Market competition, patent litigation, healthcare policies, and negotiated pricing with payers.
References
- IQVIA. (2022). Global Biosimilars Market Report.
- FDA. (2022). Approval notices for biosimilars.
- EMA. (2023). Market authorizations for biosimilars.
- EvaluatePharma. (2023). World Preview 2023.
- Reports and press releases from Novartis and peer biosimilar manufacturers.
